Poster
11
(#11) Real-World Healthcare Resource Utilization and Costs Among US Individuals Living with Bipolar-I Disorder who Transitioned to Aripiprazole 2-Month Ready-To-Use Formulation
Psych Congress 2025
Abstract: Background
Nonadherence to oral antipsychotics (OAPs) among patients diagnosed with bipolar I disorder (BP-I) is associated with increased healthcare resource utilization (HCRU) and costs. Transitioning to long-acting injectables, including aripiprazole 2-Month Ready-To-Use (Ari 2MRTU), may improve adherence and reduce HCRU.
Objective
Describe patient profiles, adherence, HCRU, and costs in adults diagnosed with BP-I who transitioned from OAPs or aripiprazole once-monthly (AOM) to Ari 2MRTU, using a pre-post-analysis.
Method
This retrospective, non-interventional database study analyzed Kythera Labs closed claims (April 2022-March 2025) to identify US adults (≥18 years) commercially or Medicaid-insured, diagnosed with BP-I who transitioned from OAPs or AOM to Ari 2MRTU (index date = Ari 2MRTU transition). Continuous enrollment for 12 months pre- and 6 months post-index was required. Outcomes included adherence, HCRU, and costs.
Results
Among those who transitioned from OAPs to Ari 2MRTU (n=371), adherence improved post-index (Proportion of Days Covered [PDC]: 0.60 to 0.76; Medication Possession Ratio [MPR]: 0.67 to 0.85; p.0001) vs 6 months pre-index date. All-cause and psychiatry-related inpatient, outpatient, and emergency (ER) utilization declined (all p.05). All-cause inpatient, ER, and total medical (inpatient, outpatient, ER) costs and psychiatry-related inpatient costs declined. Among those who transitioned from AOM to Ari 2MRTU (n=1,096), adherence improved (PDC: 0.56 to 0.81; MPR: 0.62 to 0.89; p.0001). Inpatient visits (all-cause, psychiatry-related), length of stay, and outpatient visits decreased. All-cause ER and total medical costs declined.
Conclusion
Transitioning to Ari 2MRTU improved adherence, and reduced HCRU and cost, supporting its value as a treatment option in BP-I management.
Short Description: This study examined the pre post impact on adherence, health care resource utilization, and cost among patients living with bipolar-I disorder who are transitioned to aripiprazole 2-Month Ready-To-Use formulation from oral antipsychotic therapies or aripiprazole once-monthly formulation.
Name of Sponsoring Organization(s): Otsuka Pharmaceutical Development and Commercialization, H Lundbeck A/S
Nonadherence to oral antipsychotics (OAPs) among patients diagnosed with bipolar I disorder (BP-I) is associated with increased healthcare resource utilization (HCRU) and costs. Transitioning to long-acting injectables, including aripiprazole 2-Month Ready-To-Use (Ari 2MRTU), may improve adherence and reduce HCRU.
Objective
Describe patient profiles, adherence, HCRU, and costs in adults diagnosed with BP-I who transitioned from OAPs or aripiprazole once-monthly (AOM) to Ari 2MRTU, using a pre-post-analysis.
Method
This retrospective, non-interventional database study analyzed Kythera Labs closed claims (April 2022-March 2025) to identify US adults (≥18 years) commercially or Medicaid-insured, diagnosed with BP-I who transitioned from OAPs or AOM to Ari 2MRTU (index date = Ari 2MRTU transition). Continuous enrollment for 12 months pre- and 6 months post-index was required. Outcomes included adherence, HCRU, and costs.
Results
Among those who transitioned from OAPs to Ari 2MRTU (n=371), adherence improved post-index (Proportion of Days Covered [PDC]: 0.60 to 0.76; Medication Possession Ratio [MPR]: 0.67 to 0.85; p.0001) vs 6 months pre-index date. All-cause and psychiatry-related inpatient, outpatient, and emergency (ER) utilization declined (all p.05). All-cause inpatient, ER, and total medical (inpatient, outpatient, ER) costs and psychiatry-related inpatient costs declined. Among those who transitioned from AOM to Ari 2MRTU (n=1,096), adherence improved (PDC: 0.56 to 0.81; MPR: 0.62 to 0.89; p.0001). Inpatient visits (all-cause, psychiatry-related), length of stay, and outpatient visits decreased. All-cause ER and total medical costs declined.
Conclusion
Transitioning to Ari 2MRTU improved adherence, and reduced HCRU and cost, supporting its value as a treatment option in BP-I management.
Short Description: This study examined the pre post impact on adherence, health care resource utilization, and cost among patients living with bipolar-I disorder who are transitioned to aripiprazole 2-Month Ready-To-Use formulation from oral antipsychotic therapies or aripiprazole once-monthly formulation.
Name of Sponsoring Organization(s): Otsuka Pharmaceutical Development and Commercialization, H Lundbeck A/S
